Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Emerging drugs for narcolepsy.

Vivien C Abad1, Christian Guilleminault

  • 1Clinical Monitoring Sleep Disorders Center, Camino Medical Group, Cupertino, California, USA.

Expert Opinion on Emerging Drugs
|December 2, 2004
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Awakening to sleep: Sixteen years of World Sleep Day global initiatives and future directions.

Sleep medicine·2025
Same author

Rapid maxillary expansion in COMISA: preliminary observations from a 12 years follow-up.

Sleep·2024
Same author

Pharmacological options for narcolepsy: are they the way forward?

Expert review of neurotherapeutics·2023
Same author

Treatment of obstructive sleep apnea in high risk pregnancy: a multicenter randomized controlled trial.

Respiratory research·2023
Same author

Maxillomandibular Advancement for OSA: A 25-year perspective

L' Orthodontie francaise·2023
Same author

Calcium, magnesium, potassium, and sodium oxybates oral solution for cataplexy or excessive daytime sleepiness associated with narcolepsy.

Expert opinion on pharmacotherapy·2023

Narcolepsy, a sleep disorder causing daytime sleepiness and cataplexy, is linked to the hypocretin system. Current treatments manage symptoms, but research explores novel therapies for this disabling condition.

Area of Science:

  • Neurology
  • Sleep Medicine
  • Neuroscience

Background:

  • Narcolepsy is a neurological disorder characterized by excessive daytime sleepiness, cataplexy, hallucinations, and sleep paralysis.
  • While the exact cause is unknown, genetic predisposition and environmental triggers are suspected, with the hypocretin system playing a crucial role.
  • Reduced hypocretin-1 levels in cerebrospinal fluid are observed in narcolepsy patients with cataplexy.

Purpose of the Study:

  • To summarize the current understanding of narcolepsy's pathophysiology and treatment landscape.
  • To highlight the role of the hypocretin system in narcolepsy development.
  • To review existing and emerging therapeutic strategies for narcolepsy symptoms.

Main Methods:

  • Review of existing literature on narcolepsy.

Related Experiment Videos

  • Analysis of the role of the hypocretin system in narcolepsy.
  • Categorization of current and experimental narcolepsy treatments.

    • Main Results:

    • Narcolepsy is associated with hypocretin deficiency, particularly in patients with cataplexy.
    • Current treatments include stimulants for sleepiness and antidepressants or sodium oxybate for cataplexy.
    • Experimental therapies target histamine antagonists, hypocretin agonists, and sleep enhancement.

    Conclusions:

    • Narcolepsy is a disabling condition with complex pathophysiology involving the hypocretin system.
    • Symptomatic treatments are available, but novel therapeutic approaches are under investigation.
    • Further research into the hypocretin system may lead to more effective narcolepsy treatments.